Business Wire

SAPHETOR-SA

24.7.2024 09:01:28 CEST | Business Wire | Press release

Share
Saphetor SA receives IVDR Certification for clinical diagnosis support NGS data analysis platform, VarSome Clinical, ensuring enhanced safety and performance standards

Saphetor SA, the creators of the global human genetics community VarSome, today announced European CE mark approval of the VarSome Clinical platform for the automated variant discovery, annotation, and interpretation of Next Generation Sequencing (NGS) data in compliance with the European Union’s In-Vitro Diagnostic Medical Devices Regulation (IVDR) (EU Regulation 2017/746 on IVD medical devices) by the notified body TÜV SÜD.

This represents a major milestone in clinical genomics, as robust standards and regulations are introduced to ensure the safety and effectiveness of medical devices. Inclusion of NGS analysis software under IVDR, is a reflection of the maturity of the technology and its importance in clinical practice. With this shift towards routine care, comes the need for transparency and reproducibly reliable performance.

IVDR, which came into full effect on 26 of May 2022, replaces the previous In-Vitro Diagnostic Medical Devices Directive (IVDD) and introduces more stringent requirements for the classification, performance evaluation, and post-market surveillance of in-vitro diagnostic devices. VarSome Clinical’s IVDR certification ensures that it meets the highest standards of safety, performance, and reliability.

As a result of IVDR coming into full effect, in-house tests (also known as Laboratory Developed Tests (LDTs)) or Research Use Only (RUO) products must comply with Article 5.5 of IVDR. This includes in particular the need to implement appropriate quality management systems, comply with the GSPR (General Safety & Performance Requirements) and set up a review process to take necessary corrective actions based on experience gained from the clinical use of the RUO product. At the end of the IVDR transition period, laboratories will no longer be allowed to use a RUO bioinformatics solution if an equivalent IVDR-certified product, such as VarSome Clinical, is commercially available.

Key benefits of VarSome Clinical’s IVDR certification:

  1. Enhanced safety and performance: VarSome Clinical has undergone rigorous performance evaluations, including scientific validity, analytical performance, and clinical performance, ensuring they meet the stringent requirements set forth by the IVDR.
  2. Improved risk management: The new risk-based system and comprehensive technical documentation provide a strong framework for identifying and reducing potential risks associated with in-vitro diagnostic devices.
  3. Strengthened market surveillance: With enhanced post-market surveillance measures, including vigilance reporting and periodic safety updates, Saphetor is committed to continuously monitor the performance and safety of VarSome Clinical.
  4. Transparency and traceability: Achieving better management of safety related issues and ensuring prompt actions when necessary.
  5. Regulatory excellence: VarSome Clinical’s IVDR certification demonstrates the dedication of Saphetor for regulatory excellence, providing confidence to healthcare professionals and patients in the quality and reliability of VarSome Clinical as a clinical diagnostic support solution.

Andreas Massouras, CEO and Founder, Saphetor SA, comments:
“The journey to IVDR certification has taken us more than two years. It has taken a lot of hard work across the company, and a lot of planning to put new processes in place. This now sets the new standard that all NGS diagnostic pipelines need to adhere to. Ensuring patient safety, through transparent and robust processes is crucial at this point in time. Genomic data is already having a major impact on healthcare, and so it is now critically important that it meet the standards that the rest of established medical practices have to meet. This is an exciting time, as it shows that genomics is now moving beyond clinical research and into routine clinical care. We are exceptionally proud to be amongst the first bioinformatics platforms to be awarded a CE mark under IVDR, and we look forward to continuing to help advance human health with our VarSome Clinical partners.”

Amélie Martinez, RAQA Director, Saphetor SA, comments:
“This certification is a great achievement and rewards all our efforts in meeting the IVDR requirements, both with the medical device documentation and our Quality Management System. We are proud to be able to provide Healthcare Professionals and diagnostic labs with an IVDR-compliant device, thus reducing their workload for process validation and giving them more time to care for patients.”

About Saphetor SA
Saphetor SA, is a global precision-medicine company dedicated to large-scale identification and interpretation of human genetic variants by leveraging proprietary algorithms and expert domain knowledge.
Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions both for clinicians and researchers. VarSome.com professional community and search engine is freely accessible, featuring a widely-recognized community-driven knowledge base that enables flexible queries across more than 140 genetic and genomic data resources.
VarSome Premium and VarSome Clinical are professional editions of VarSome with powerful functionality and further sophisticated data-mining and analysis tools. VarSome Clinical is a IVDR-certified and HIPAA-compliant platform allowing fast and accurate variant discovery, annotation, and interpretation of NGS data for whole genomes, exomes, and gene panels, which helps clinicians reach faster and more accurate diagnoses and treatment decisions for genetic conditions. VarSome can also be integrated into existing in-house pipelines via VarSome API through cloud-based or on premises installations.

For more information about Saphetor SA and VarSome Clinical, please visit www.saphetor.com or contact sales@varsome.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724536462/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release

New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 08:00:00 CET | Press release

Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release

Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token

NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press release

NETS becomes the first national payment rail to join Ant International’s Agentic Mobile ProtocolNETS and Ant International’s MOU signing signals commitment to deepen the companies’ long-standing collaboration since 2023The partnership aims to deliver comprehensive AI-native merchant solutions to expand reach and lift operational efficiency Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye